Irodanoprost
CAS 2055490-48-5
MF C34H44F2N2O13P2 MW788.7 g/mol
7-[(2R)-2-[(E,3R)-4,4-difluoro-3-[2-[4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl]acetyl]oxy-4-phenylbut-1-enyl]-5-oxopyrrolidin-1-yl]heptanoic acid
- 1-Pyrrolidineheptanoic acid, 2-[(1E,3R)-4,4-difluoro-3-[[2-[4-[[(4-hydroxy-4,4-diphosphonobutyl)amino]carbonyl]phenyl]acetyl]oxy]-4-phenyl-1-buten-1-yl]-5-oxo-, (2R)-
- 7-[(2R)-2-{(1E,3R)-4,4-difluoro-3-[({4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl}acetyl)oxy]-4-phenylbut-1-en-1-yl}-5-oxopyrrolidin-1-yl]heptanoic acid
7-[(2R)-2-{(1E,3R)-4,4-difluoro-3-[({4-[(4-hydroxy-4,4-diphosphonobutyl)carbamoyl]phenyl}acetyl)oxy]-4-phenylbut-1-en-1-yl}-5-oxopyrrolidin-1-yl]heptanoic acid
prostaglandin receptor agonist, osteogenesis-related diseases, KP8BK46Z6R, MES 1022
Irodanoprost (also known as MES-1022) is a clinical-stage, bone- and pathology-targeted small molecule prodrug that acts as a potent and selective agonist for the prostaglandin E2 receptor subtype 4 (EP4). Developed by the pharmaceutical company Mesentech Inc., the compound is designed to treat severe musculoskeletal and rare muscle-wasting diseases
Therapeutic Mechanism
Systemic activation of the EP4 receptor has long been known to stimulate bone and muscle regeneration. However, its clinical use was previously restricted due to toxic off-target side effects like severe hypotension and gastrointestinal issues.
Irodanoprost overcomes this barrier through a unique “pathology-targeted” conjugate design:
- Targeting Mechanism: The EP4 agonist is chemically linked to a moiety that binds selectively to calcium-rich tissues—such as bone matrices or damaged, dystrophic muscle fibers.
- Local Activation: Once it accumulates at the site of damage, it delivers localized therapeutic signaling while avoiding systemic tissues.
Primary Target Indications
The drug candidate is primarily under investigation for several rare or progressive degenerative diseases:
- Duchenne Muscular Dystrophy (DMD): Preclinical trials on advanced DMD rat models published in bioRxiv demonstrate that irodanoprost actively blocks the differentiation of fibro-adipogenic progenitors, effectively reversing established muscle fibrosis and restoring muscle mass to wild-type levels.
- Osteogenesis Imperfecta (Brittle Bone Disease): Utilizing its bone-anabolic pathway to promote bone growth and strength.
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Osteoporosis
PAT
EP-3307747-A1 US-10400000-B2 US-11312737-B2 US-20180170951-A1 US-20190345179-A1 WO-2016199111-A1
PAT
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016199111&_cid=P11-MQ7G6Y-06859-1
ADVERTISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
PAT
- Amide-linked EP4 agonist-bisphosphonate compounds and uses thereofPublication Number: US-10400000-B2Priority Date: 2015-06-12Grant Date: 2019-09-03
- Amide-linked ep4 agonist-bisphosphonate compounds and uses thereofPublication Number: US-2019345179-A1Priority Date: 2015-06-12
- Amide-linked ep4 agonist-bisphosphonate compounds and uses thereofPublication Number: US-2018170951-A1Priority Date: 2015-06-12
- Amide-linked ep4 agonist-bisphosphonate compounds and uses thereofPublication Number: WO-2016199111-A1Priority Date: 2015-06-12
- Amide-linked ep4 agonist-bisphosphonate compounds and uses thereofPublication Number: EP-3307747-A1Priority Date: 2015-06-12
- Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
- Publication Number: US-11312737-B2
- Priority Date: 2015-06-12
- Grant Date: 2022-04-26
////////////irodanoprost, ANAX LABS, prostaglandin receptor agonist, osteogenesis-related diseases, KP8BK46Z6R, MES 1022